医学
ROS1型
克里唑蒂尼
内科学
胃肠病学
置信区间
耐火材料(行星科学)
腺癌
癌症
肺癌
物理
天体生物学
恶性胸腔积液
作者
Sai‐Hong Ignatius Ou,Yutaka Fujiwara,Alice T. Shaw,Noboru Yamamoto,Kazuhiko Nakagawa,Frank Fan,Yuki Hao,Yanfei Gao,Pasi A. Jänne,Takashi Seto
标识
DOI:10.1016/j.jtocrr.2020.100108
摘要
Taletrectinib (AB106/DS6051b) has a meaningful clinical activity in patients with advanced ROS1+ NSCLC who are ROS1 TKI-naive or crizotinib-refractory and a manageable safety profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI